MedPath

BECTON, DICKINSON AND COMPANY

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
menafn.com
·

Global Biotechnology Market Outlook 2025: Driving Growth At 13.0% CAGR

The Global Biotech Industry Outlook for 2025 highlights AI integration in drug discovery, innovative therapies like CRISPR and cell/gene therapy, and strategic collaborations. Key developments include AI-powered tools for drug candidate identification and clinical trial optimization, with major players investing in R&D and ATMPs. The industry anticipates growth in precision medicine, GLP-1 receptor agonists, and sustainability practices.
prnewswire.co.uk
·

Global Biotechnology Market Outlook 2025: Driving Growth at 13.0% CAGR

The global biotechnology market is projected to grow from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, at a CAGR of ~13.0%. Growth is driven by innovation, M&A, investments, and focus on advanced therapies like personalized medicine, AI in drug discovery, and biologics. Key trends include CRISPR-based therapies, AI-powered tools, and sustainability in biomanufacturing.
prnewswire.com
·

Global Biotechnology Market Outlook 2025: Driving Growth

The global biotechnology market is projected to grow from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, at a CAGR of ~13.0%. Growth is driven by innovation, M&A, investments, and advanced therapies like personalized medicine, AI integration, and biologics. Key trends include CRISPR-based therapies, AI in drug discovery, and sustainability in biomanufacturing.

Oligonucleotide Synthesis Market Report 2025: RNA-Based Vaccines, Genomic Blizzard, Antisense Revival, & New Applications Driving Growth

The article outlines the oligonucleotide synthesis market, covering synthesis technology, applications, industry players, market factors, recent developments, and global market overview. It highlights advancements in synthesis technology, the role of diagnostics, and the impact of COVID-19, alongside profiles of key companies and market segmentation by length, application, product, category, and type.
pharmiweb.com
·

Injection Pen Industry to Surpass USD 85.8 Billion by 2033, Growing at a 7.0% CAGR

The global injection pen market is projected to grow from USD 40.7 billion in 2022 to USD 85.8 billion by 2033, driven by chronic disease prevalence, technological advancements, and the shift towards self-administered drug delivery. Innovations like digital pens enhance patient monitoring and treatment adherence.
globenewswire.com
·

Microfluidics Global Market Research 2024-2029

The Microfluidics market is projected to grow from USD 22.43 Billion in 2024 to USD 32.67 Billion by 2029, at a CAGR of 7.8%. Growth drivers include demand for point-of-care diagnostics, innovations in drug delivery, and personalized medicine. Polymers lead the market due to cost-effectiveness and versatility. Asia Pacific is expected to see the highest growth rate.
globenewswire.com
·

Microbiome Diagnostics Research Report 2024: Global Market

The Microbiome Diagnostics Market, valued at USD 145.48 Million in 2023, is projected to reach USD 261.84 Million by 2029, growing at a CAGR of 10.25%. Growth is driven by personalized medicine, early disease detection, and chronic disease management. North America leads, with 16S rRNA sequencing dominating. Key players include DNA Genotek Inc and Illumina, Inc.
finance.yahoo.com
·

BD and Babson expand fingertip blood testing across US health systems

BD and Babson Diagnostics have enhanced US healthcare access by integrating BD's MiniDraw and Babson's BetterWay for less invasive fingertip blood testing. This innovation, requiring only six drops of blood, aims to improve efficiency, patient satisfaction, and outcomes, especially in underserved areas. Their partnership, ongoing since 2016, now extends to retail settings, broadening patient access to blood collection services.
massdevice.com
·

BD to pay SEC $175M to settle Alaris investigation

BD agreed to pay $175M to SEC to settle Alaris system investigation, neither admitting nor denying findings. The company faced setbacks with Alaris, including a 2020 shipping hold, and previously settled a class action suit for $85M. BD believes settling with SEC resolves the matter and allows forward progress.
news.bd.com
·

BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations

BD and Babson Diagnostics expand fingertip blood testing, integrating BD's MiniDraw™ with Babson's BetterWay tech, enabling testing with six drops of blood, improving access and reducing barriers in underserved areas.
© Copyright 2025. All Rights Reserved by MedPath